References
- Drucker D Nauck M The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 Nov 11 368 9548 1696 705
- Holst JJ Orskov C Nielsen OV Schwartz TW Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut FEBS Lett 1987 Jan 26 211 2 169 74
- Kreymann B Williams G Ghatei MA Bloom SR Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 1987 Dec 5 2 8571 1300 4
- Mehta A Marso SP Neeland IJ Liraglutide for weight management: a critical review of the evidence Obes Sci Pract 2017 Mar 3 1 3 14
- Holst JJ Deacon CF Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors Diabetologia 2005 Apr 48 4 612 5
- Abdul-Ghani MA DeFronzo RA Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus Endocr Pract 2008 Sep 14 6 782 90
- Nair S Wilding J Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 2010 Jan 95 1 34 42
- Nauck MA Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des Devel Ther 2014 Sep 11 8 1335 80
- Mazidi M Rezaie P Gao HK Kengne AP Effect of Sodium-Glucose Cotrans-port-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients J Am Heart Assoc 2017 May 25 6 6
- U. S. Food and Drug Administration [Internet] Silver Spring, MD U.S. Food and Drug Administration c2018 Guidance for Industry: Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes: 2008 Dec [cited 2018 Aug 2]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
- Green J Bethel M Armstrong P TECOS Study Group Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2015 Jul 16 373 3 232 42
- Röhrborn D Wronkowitz N Eckel J DPP4 in Diabetes Front Immunol 2015 Jul 27 6 386
- Scirica B Bhatt D Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 Oct 3 369 14 1317 26
- White W Cannon C Heller S EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 Oct 3 369 14 1327 35
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2010–2018 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes; 2010 Nov 18 [cited 2018 Jul 2]. Available from: https://clinicaltrials.gov/ct2/show/NCt101243424
- Pfeffer M Claggett B Diaz R ELIXA Investigators Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med 2015 Dec 3 373 23 2247 57
- Marso S Daniels G Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2016 Jul 28 375 4 311 22
- Marso S Bain S Consoli A SUSTAIN-6 Investigators Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 2016 Nov 10 375 19 1834 44
- Holman R Bethel M Mentz R Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2017 Sep 28 377 13 1228 39
- Davies M Bain S Atkin S Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial Diabetes Care 2016 Feb 39 2 222 30
- Astrup A Rössner S Van Gaal L NN8022-1807 Study Group Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 2009 Nov 7 374 9701 1606 16
- Astrup A Carraro R Finer N Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide Int J Obes (Lond) 2012 Jun 36 6 843 54
- Zinman B Wanner C Lachin J Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 2015 Nov 26 373 22 2117 28
- Neal B Perkovic V Mahaffey K CANVAS Program Collaborative Group Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017 Aug 17 377 7 644 57
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2012–2018 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58); 2012 Nov 21 [cited 2018 Jul 2]. Available from: https://clinicaltrials.gov/ct2/show/NCt101730534
- Bhartia M Tahrani A Barnett A SGLT-2 inhibitors in development for type 2 diabetes treatment Rev Diabet Stud 2011 Fall 8 3 348 54
- Ruanpeng D Ungprasert P Sangtian J Harindhanavudhi T Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis Diabetes Metab Res Rev 2017 Sep 33 6
- Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan 41 S1 S73 85
- Garber AJ Abrahamson MJ Barzilay JI Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary Endocr Pract 2018 Jan 24 1 91 120
- Kim H Park S Ko S Committee of Clinical Practice Guidelines of the Korean Diabetes Association Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association Diabetes Metab J 2017 Dec 41 6 423 9
- Inzucchi S Bergenstal R Buse J Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 Jan 38 1 140 9
- GoodRx [Internet] Santa Monica, CA GoodRx, Inc. c2018 [cited 2018 Jul 2]. Available from: https://www.goodrx.com
DOI: https://doi.org/10.14797/mdcj-14-4-281 | Journal eISSN: 1947-6108
Language: English
Page range: 281 - 288
Published on: Oct 1, 2018
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2018 Ahmad Yehya, Archana R. Sadhu, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.